Form 483

Boston Scientific Corporation Form 483, 2021-11-18

FDA issued a Form 483 to Boston Scientific Corporation on 2021-11-18 with 5 public-safe observations.

483· Form 483 issuedMedical Devices & Rad Health5 observations

Boston Scientific Corporation · Saint Paul, United States · Issued November 18, 2021

Overview

  • 5 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

18 Nov 2021
21 CFR 58.120(a)(9)

Protocol: tests, analyses, and measurements

Cited by Nicole C Victoria, Sharon L Matson

18 Nov 2021
21 CFR 58.195(b)

Archives: retention for appropriate time

Cited by Nicole C Victoria, Sharon L Matson

18 Nov 2021
21 CFR 58.33(b)

Study director: all data recorded and verified

Cited by Nicole C Victoria, Sharon L Matson

18 Nov 2021
21 CFR 58.35(a)

QAU: monitor facilities, etc.

Cited by Nicole C Victoria, Sharon L Matson

18 Nov 2021
21 CFR 58.83

Reagents: labeling

Cited by Nicole C Victoria, Sharon L Matson

Inspected site

BSBoston Scientific CorporationSaint Paul, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 58.120(a)(9)Cited across public-safe Form 483 observations1x
21 CFR 58.195(b)Cited across public-safe Form 483 observations1x
21 CFR 58.33(b)Cited across public-safe Form 483 observations1x
21 CFR 58.35(a)Cited across public-safe Form 483 observations1x
21 CFR 58.83Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 5 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere